FDA Approves Cerus Anti-Pathogen System For Safer Blood Transfusions
This article was originally published in The Gray Sheet
Executive Summary
The system is meant to proactively kill bacteria and viruses that may otherwise go unnoticed, and has already proven effective in removing dangerous pathogens without increasing risk to patients according to the agency.
You may also be interested in...
Pathogen-Reduction Tech Gets Some Focus At FDA Panel Meeting, But Not Enough, Cerus Says
While a panel of US FDA experts agreed that pathogen reduction technology is a promising strategy for reducing blood platelet contaminations, they raised concerns about the cost of implementing the technology. The maker of the technology, Cerus, says the panel was under-briefed and distracted.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.